Compositions and methods for inhibition of MMP13:MMP-substrate interactions
AssigneeProteapex Therapeutics, LLC
InventorsMarina D'Angelo, Abdulhafez Selim
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGFβ). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.
Claims13
A synthetic compound with binding affinity for a matrix metalloprotease (MMP) substrate protein, wherein the compound is able to competitively inhibit binding of MMP13 to the substrate protein,
- wherein the compound comprises a peptide or peptide mimetic of less than 50 amino acids, and
- wherein the compound comprises a sequence greater than about 50% identical to SEQ ID NO:36.
Dependencies are inferred from the claim text.